Dong-A ST, AI Company Simplex Collaborate on CNS New Drug Development
[Asia Economy Reporter Kim Ji-hee] Dong-A ST announced on the 30th that it has signed a joint research and development and licensing agreement with Simplex, an artificial intelligence (AI)-based new drug development company, for the development of new drugs for central nervous system (CNS) diseases.
Simplex is an AI-based new drug development company founded in 2017 by CEO Cho Sung-jin, who majored in medicinal chemistry and has experience in developing new drug development platforms. In October last year, it attracted Series A investment worth 5 billion KRW and is promoting the development of its own new drug pipeline as well as collaboration with numerous pharmaceutical companies and bio ventures.
Dong-A ST will be responsible for verifying and commercializing the active substances and candidate substances of CNS disease new drugs discovered by Simplex. Simplex will be in charge of discovering new drug candidates through the search and optimization of active substances in computer simulation virtual experiments using its own AI platform technology.
The rights to the candidate substances will be jointly owned by both companies. The implementation rights will be held by Dong-A ST.
Yang Seung-min, head of Dong-A ST’s new drug research institute, said, “Dong-A ST has long accumulated know-how in new drug development with an interest in degenerative brain diseases among CNS diseases,” and added, “We hope that new drug candidates can be rapidly derived through Simplex’s AI platform based on medicinal chemistry.”
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Cho Sung-jin, CEO of Simplex, said, “It is meaningful to become Dong-A ST’s first AI new drug development partner, a company with accumulated technology and experience in new drug development,” and added, “The synergy between Simplex’s differentiated AI platform and Dong-A ST’s new drug development capabilities will dramatically improve the efficiency of new drug development.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
